Affimed Therapeutics AG, a Heidelberg, Germany-based developer of antibody therapeutics, has raised EUR 25 million in Series B funding. Participants included BioMedInvest, OrbiMed Advisors, Life Sciences Partners and return backer FirstVentury. The company's two lead clinical programs focus on the treatment of Hodgkin's disease and Non-Hodgkin's Lymphoma, respectively. www.affimed.com
Nearly there!
We have just sent you an email so you can verify your account. Please check your spam or junk folder just in case
it’s been delivered there.
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.
Copyright PEI Media
Not for publication, email or dissemination
Share with other subscribers
Only logged in subscribers of this site will be able to access the shared article.
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.